Immupharma Plc · LSE:IMM
Immupharma — Investor Presentation (April 2020)
15 slides from Immupharma's investor presentation, April 2020
Slide 1: Developing Innovative Peptides
plc Developing Innovative Peptides April 2020
Slide 2: ImmuPharma
ImmuPharma • Listed on AIM (LSE:IMM) & Euronext Growth Brussels (ALIMM) • Pipeline of innovative peptide products • Portfolio from early to late stage • Lupuzor™ - lead product for Lupus - gearing up to start optimised Phase III international trial • US partner ‘Avion’ signed in Q4 2019 - funding Lu
Slide 3: Recent update
Recent update £1.5 million Subscription • Issue of 15,000,000 new ordinary shares of 10P each comprising: o £200k from Dr Robert Zimmer (President & CSO of IMM) o £1.3m with Lanstead Capital (major shareholder) • Proceeds will be used primarily to fund: o Expansion of the Company’s R&D programmes; a
Slide 4: £1.3m Lanstead Subscription
£1.3m Lanstead Subscription 13m shares placed with Lanstead at 10p per share = £1.3m IMM receives the proceeds back over 24 months starting in July 2020 Amount received on monthly basis dependent on 20-day volume weighted average share price (VWAP) each month If VWAP exceeds 13.33p Benchmark
Slide 5: Key programmes
Key programmes Autoimmunity Metabolism Lupuzor™ for Lupus BioGlucagon & CIDP Innovative Peptides Anti- infective BioAmp-B 5
Slide 6: Lupuzor™
Lupuzor™ • Lupuzor™ (forigerimod) is more than just Lupus • Many more indications • Multifunctional • Underlying mechanism of action of Lupus occurs in other diseases 6
Slide 7: Lupuzor™ for Lupus
Lupuzor™ for Lupus Lupus • Autoimmune chronic inflammatory disease • Unmet market need - lack of safe and effective treatments • Multi-billion sales potential • Patients*: >5m globally | 1.5m lupus sufferers in EU/US/Japan • GSK’s approval of Benlysta in 2011 paves the path to market Lupuzor™ • Nove
Slide 8: Lupuzor™ fully funded for lupus – US deal with Avion
Lupuzor™ fully funded for lupus – US deal with Avion • New ‘optimized’ international Phase III trial • Exclusive rights for US with Avion • Lupuzor ™ Phase III funded up to $25m • Milestones up to $70m & tiered double-digit HQ: Georgia USA with >200 employees Fully integrated in drug development
Slide 9: Avion’s strengthened advisory team
Avion’s strengthened advisory team • Collaboration with leading Lupus patient group & formation of Board of KOLs • Key decisions/next steps agreed prior to FDA meeting to include: • Structure of optimised intl. Phase III Lupuzor™ trial • Demographics and patient inclusion criteria • Guidance on key
Slide 10: Lupuzor™ for CIDP
Lupuzor™ for CIDP • CIDP* is a neurological disorder targeting the body’s nerves • Symptoms: fatigue and weakness, numbness, tingling in limbs • Unique MOA** of Lupuzor™*** demonstrates effectiveness in auto- immune diseases including ‘CIDP’ • CIDP could be granted ‘Orphan Drug Designation’ due to t
Slide 11: Metabolism – ‘New’ BioGlucagon
Metabolism – ‘New’ BioGlucagon • BioGlucagon is a potential new rescue therapy for low sugar events in diabetes • Existing glucagon products; poor solubility, inconvenient - variable dosing creates risks for patients • BioGlucagon has 100% solubility, can be formulated in pre-filled syringe pens and
Slide 12: Anti-Infectives – ‘New’ BioAMP-B
Anti-Infectives – ‘New’ BioAMP-B Anti-fungal opportunity • BioAMP-B is a novel peptide-based drug that offers a potential improvement on Amphotericin-B (“Amp-B”) • Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection) • Le
Slide 13: Not just a Lupus story - value enhancing news flow & milestones
Not just a Lupus story - value enhancing news flow & milestones 2020 2021 2022 Avion Phase III Lupuzor™ Avion Phase III Lupuzor™ Avion Phase III Lupuzor™ progress updates progress updates progress updates Autoimmunity CIDP ‘POC’ preparation CIDP ‘POC’ study Lupuzor™ ex US partnering opportunities Bi
Slide 14: Investment summary
Investment summary • Latest investment from Lanstead • Strong endorsement of IMM’s technology platform • Lupuzor™ fully funded by US partner Avion • Moving into optimised Phase III intl. trial • Near term inflexion points • Continued strong news flow • Partnering opportunities • Lupuzor™ in key terr
Slide 15: actual results to differ materially from those projected or suggeste a ir
15 actual results to differ materially from those projected or suggeste a ir These factors include, but are not limited to: (i) ImmuPharma’s and/o ers’ ability to ict research an studies and commercialisation; (ii) ImmuPharma’s and/or ImmuPh to obtain require including prodt pharmaceutical industry